Novel agents to inhibit microbial virulence and pathogenicity

Importance of the field: The rising levels of antibiotic resistance in pathogenic microorganisms create an urgent need for new antimicrobial agents that are not affected by resistance mechanisms already present in the bacterial population. Targeting virulence is one of the alternative approaches to find new molecules to treat infections due to resistant bacteria. Novel strategies to identify these new antimicrobial agents have been reported. Areas covered in this review: A variety of virulence factors are now the target for inhibition mainly in the antibacterial field. This review focuses exclusively on the new virulence inhibitors published in patents (worldwide collection of patents filed) or in the literature since 2006. What the reader will gain: New efficacy in vitro assays have been developed allowing screening of large numbers of molecules. These inhibitors are mainly antibacterial molecules, a few natural products, peptides and antibodies. A growing number of these published studies provide results showing a proof of concept with antivirulence compounds that were able to prevent or treat an infection in vivo. Moreover, some new antivirulence agents could inhibit virulence mechanisms that are common to different related pathogenic species, extending the potential spectrum of antivirulence compounds. Take home message: The progress reported recently for antivirulence molecules at the preclinical stages should allow new classes of molecules to enter into development as new antimicrobial agents with new mechanisms of action.

[1]  D. Higgins,et al.  Genomic approaches to understanding bacterial virulence. , 2007, Current opinion in microbiology.

[2]  A. D'Antoni,et al.  Update on the antibacterial resistance crisis. , 2007, Medical science monitor : international medical journal of experimental and clinical research.

[3]  Kathrine B. Christensen,et al.  Identity and effects of quorum-sensing inhibitors produced by Penicillium species. , 2005, Microbiology.

[4]  Francis C. Neuhaus,et al.  A Continuum of Anionic Charge: Structures and Functions of d-Alanyl-Teichoic Acids in Gram-Positive Bacteria , 2003, Microbiology and Molecular Biology Reviews.

[5]  P. Nordström,et al.  Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle , 2007, FEBS letters.

[6]  C. Whitfield,et al.  Lipopolysaccharide endotoxins. , 2002, Annual review of biochemistry.

[7]  S. Kang,et al.  Flavonols inhibit sortases and sortase-mediated Staphylococcus aureus clumping to fibrinogen. , 2006, Biological & pharmaceutical bulletin.

[8]  Hans Wolf-Watz,et al.  Protein delivery into eukaryotic cells by type III secretion machines , 2006, Nature.

[9]  G. Marshall,et al.  The biology and future prospects of antivirulence therapies , 2008, Nature Reviews Microbiology.

[10]  R. Tompkins,et al.  Inhibitors of Pathogen Intercellular Signals as Selective Anti-Infective Compounds , 2007, PLoS pathogens.

[11]  N. Desroy,et al.  Towards Gram-negative antivirulence drugs: new inhibitors of HldE kinase. , 2009, Bioorganic & medicinal chemistry.

[12]  D. Pompliano,et al.  Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.

[13]  Natalie G Ahn,et al.  Proteomics and genomics: perspectives on drug and target discovery , 2008, Current Opinion in Chemical Biology.

[14]  M. Schmid,et al.  Large-Scale Identification of Genes Required for Full Virulence of Staphylococcus aureus , 2004, Journal of bacteriology.

[15]  L. Marraffini,et al.  Sortases and the Art of Anchoring Proteins to the Envelopes of Gram-Positive Bacteria , 2006, Microbiology and Molecular Biology Reviews.

[16]  G. Talbot What is in the pipeline for Gram-negative pathogens? , 2008, Expert review of anti-infective therapy.

[17]  G. Fischer,et al.  Phase 1/2 Double-Blind, Placebo-Controlled, Dose Escalation, Safety, and Pharmacokinetic Study of Pagibaximab (BSYX-A110), an Antistaphylococcal Monoclonal Antibody for the Prevention of Staphylococcal Bloodstream Infections, in Very-Low-Birth-Weight Neonates , 2009, Antimicrobial Agents and Chemotherapy.

[18]  M. Cámara,et al.  Quorum sensing and environmental adaptation in Pseudomonas aeruginosa: a tale of regulatory networks and multifunctional signal molecules. , 2009, Current opinion in microbiology.

[19]  S. Levy,et al.  Targeting virulence to prevent infection: to kill or not to kill? , 2004 .

[20]  K. Mathee,et al.  Inhibition of Quorum Sensing-Controlled Virulence Factor Production in Pseudomonas aeruginosa by South Florida Plant Extracts , 2007, Antimicrobial Agents and Chemotherapy.

[21]  S. Levy,et al.  N-hydroxybenzimidazole inhibitors of the transcription factor LcrF in Yersinia: novel antivirulence agents. , 2009, Journal of medicinal chemistry.

[22]  M. Marahiel,et al.  Inhibition of the D‐alanine:D‐alanyl carrier protein ligase from Bacillus subtilis increases the bacterium's susceptibility to antibiotics that target the cell wall , 2005, The FEBS journal.

[23]  Junguk Park,et al.  Infection control by antibody disruption of bacterial quorum sensing signaling. , 2007, Chemistry & biology.

[24]  Markus K. Dahlgren,et al.  Design, synthesis, and multivariate quantitative structure-activity relationship of salicylanilides--potent inhibitors of type III secretion in Yersinia. , 2007, Journal of medicinal chemistry.

[25]  Sanghee Kim,et al.  Discovery of diarylacrylonitriles as a novel series of small molecule sortase A inhibitors. , 2004, Journal of medicinal chemistry.

[26]  A. Joachimiak,et al.  Activation of Inhibitors by Sortase Triggers Irreversible Modification of the Active Site* , 2007, Journal of Biological Chemistry.

[27]  E. Greenberg,et al.  Generation of Virulence Factor Variants in Staphylococcus aureus Biofilms , 2007, Journal of bacteriology.

[28]  J. Boyce,et al.  A Heptosyltransferase Mutant of Pasteurella multocida Produces a Truncated Lipopolysaccharide Structure and Is Attenuated in Virulence , 2004, Infection and Immunity.

[29]  Minyong Li,et al.  Inhibitors and antagonists of bacterial quorum sensing , 2009, Medicinal research reviews.

[30]  V. Saba,et al.  Treatment of Staphylococcus aureus Biofilm Infection by the Quorum-Sensing Inhibitor RIP , 2007, Antimicrobial Agents and Chemotherapy.

[31]  C. Sasakawa,et al.  Host-microbe interaction: bacteria , 2006 .

[32]  Yuehong Wang,et al.  Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents , 2010, Proceedings of the National Academy of Sciences.

[33]  C. Weidenmaier,et al.  Teichoic acids and related cell-wall glycopolymers in Gram-positive physiology and host interactions , 2008, Nature Reviews Microbiology.

[34]  J. Goguen,et al.  Targeting Type III Secretion in Yersinia pestis , 2008, Antimicrobial Agents and Chemotherapy.

[35]  D. Livermore Has the era of untreatable infections arrived? , 2009, The Journal of antimicrobial chemotherapy.

[36]  A. Marra Targeting Virulence for Antibacterial Chemotherapy , 2006 .

[37]  Samuel I. Miller,et al.  Synthesis of and evaluation of lipid A modification by 4-substituted 4-deoxy arabinose analogs as potential inhibitors of bacterial polymyxin resistance. , 2008, Bioorganic & medicinal chemistry letters.

[38]  S. Levy,et al.  Novel anti-infection agents: small-molecule inhibitors of bacterial transcription factors. , 2007, Bioorganic & medicinal chemistry letters.

[39]  Michael Roth,et al.  Targeting QseC Signaling and Virulence for Antibiotic Development , 2008, Science.

[40]  Minyong Li,et al.  Pyrogallol and its analogs can antagonize bacterial quorum sensing in Vibrio harveyi. , 2008, Bioorganic & medicinal chemistry letters.

[41]  H. Monteil,et al.  Regulation of virulence determinants in Staphylococcus aureus: complexity and applications. , 2004, FEMS microbiology reviews.

[42]  J. Mekalanos,et al.  Virstatin inhibits dimerization of the transcriptional activator ToxT , 2007, Proceedings of the National Academy of Sciences.

[43]  V. Nizet,et al.  A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. , 2008, Science.

[44]  H. G. Boman,et al.  Antibacterial peptides: basic facts and emerging concepts , 2003, Journal of internal medicine.

[45]  Christoph Freiberg,et al.  Functional genomics in antibacterial drug discovery. , 2005, Drug discovery today.

[46]  J. Pinkner,et al.  Design, synthesis and evaluation of peptidomimetics based on substituted bicyclic 2-pyridones-targeting virulence of uropathogenic E. coli. , 2006, Bioorganic & medicinal chemistry.

[47]  C. Aldrich,et al.  Aryl acid adenylating enzymes involved in siderophore biosynthesis: fluorescence polarization assay, ligand specificity, and discovery of non-nucleoside inhibitors via high-throughput screening. , 2008, Biochemistry.

[48]  S. Kjelleberg,et al.  Impact of Pseudomonas aeruginosa quorum sensing on biofilm persistence in an in vivo intraperitoneal foreign-body infection model. , 2007, Microbiology.

[49]  V. Fowler,et al.  Reduced Susceptibility of Staphylococcus aureus to Vancomycin and Platelet Microbicidal Protein Correlates with Defective Autolysis and Loss of Accessory Gene Regulator (agr) Function , 2005, Antimicrobial Agents and Chemotherapy.

[50]  W. Vollmer,et al.  A Functional dlt Operon, Encoding Proteins Required for Incorporation of d-Alanine in Teichoic Acids in Gram-Positive Bacteria, Confers Resistance to Cationic Antimicrobial Peptides in Streptococcus pneumoniae , 2006, Journal of bacteriology.

[51]  M. Gurney,et al.  Selective killing of nonreplicating mycobacteria. , 2008, Cell host & microbe.

[52]  T. Tolker-Nielsen,et al.  Computer-Aided Identification of Recognized Drugs as Pseudomonas aeruginosa Quorum-Sensing Inhibitors , 2009, Antimicrobial Agents and Chemotherapy.

[53]  Samuel I. Miller,et al.  An inhibitor of gram-negative bacterial virulence protein secretion. , 2008, Cell host & microbe.

[54]  S. Lory,et al.  Multiple sensors control reciprocal expression of Pseudomonas aeruginosa regulatory RNA and virulence genes. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[55]  S. Molin,et al.  Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. , 2004, The Journal of antimicrobial chemotherapy.

[56]  K. A. Fields,et al.  Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle , 2006, Molecular microbiology.

[57]  C. Aldrich,et al.  Inhibition of siderophore biosynthesis in Mycobacterium tuberculosis with nucleoside bisubstrate analogues: structure-activity relationships of the nucleobase domain of 5'-O-[N-(salicyl)sulfamoyl]adenosine. , 2008, Journal of medicinal chemistry.

[58]  Samuel I. Miller,et al.  Tethered thiazolidinone dimers as inhibitors of the bacterial type III secretion system. , 2009, Bioorganic & medicinal chemistry letters.

[59]  Bonnie L Bassler,et al.  A quorum-sensing antagonist targets both membrane-bound and cytoplasmic receptors and controls bacterial pathogenicity. , 2009, Molecular cell.

[60]  Nadine H. Elowe,et al.  An in vitro screen of bacterial lipopolysaccharide biosynthetic enzymes identifies an inhibitor of ADP-heptose biosynthesis. , 2006, Chemistry & biology.

[61]  S. Escaich Antivirulence as a new antibacterial approach for chemotherapy. , 2008, Current opinion in chemical biology.

[62]  R. Kruger,et al.  Inhibition of the Staphylococcus aureus sortase transpeptidase SrtA by phosphinic peptidomimetics. , 2004, Bioorganic & medicinal chemistry.

[63]  M. Marahiel,et al.  Inhibition of aryl acid adenylation domains involved in bacterial siderophore synthesis , 2006, The FEBS journal.

[64]  R. Hancock,et al.  Cationic host defense (antimicrobial) peptides. , 2006, Current opinion in immunology.

[65]  Nicola C. Reading,et al.  The two-component system QseEF and the membrane protein QseG link adrenergic and stress sensing to bacterial pathogenesis , 2009, Proceedings of the National Academy of Sciences.

[66]  A. Clatworthy,et al.  Targeting virulence: a new paradigm for antimicrobial therapy , 2007, Nature Chemical Biology.

[67]  Edouard E Galyov,et al.  Inhibition of Type III Secretion in Salmonella enterica Serovar Typhimurium by Small-Molecule Inhibitors , 2007, Antimicrobial Agents and Chemotherapy.

[68]  Dacheng Ren,et al.  Quorum sensing inhibitors: a patent overview , 2009, Expert opinion on therapeutic patents.

[69]  C. D. Andersson,et al.  Inhibitors of type III secretion in Yersinia: design, synthesis and multivariate QSAR of 2-arylsulfonylamino-benzanilides. , 2007, Bioorganic & medicinal chemistry.

[70]  A. Marra Targeting virulence for antibacterial chemotherapy: identifying and characterising virulence factors for lead discovery. , 2006, Drugs in R&D.

[71]  Evan D. Brutinel,et al.  Control of gene expression by type III secretory activity. , 2008, Current opinion in microbiology.

[72]  M. Marahiel,et al.  Siderophore-Based Iron Acquisition and Pathogen Control , 2007, Microbiology and Molecular Biology Reviews.

[73]  Y. Shai,et al.  Lipopolysaccharide (Endotoxin)-host defense antibacterial peptides interactions: role in bacterial resistance and prevention of sepsis. , 2006, Biochimica et biophysica acta.

[74]  C. Baron Antivirulence drugs to target bacterial secretion systems. , 2010, Current opinion in microbiology.

[75]  M. Gilmore,et al.  Staphylococcus aureus—Probing for Host Weakness? , 2008, Journal of bacteriology.

[76]  T. Muir,et al.  Cyclic peptide inhibitors of staphylococcal virulence prepared by Fmoc-based thiolactone peptide synthesis. , 2008, Journal of the American Chemical Society.

[77]  O. Holst,et al.  Alanine Esters of Enterococcal Lipoteichoic Acid Play a Role in Biofilm Formation and Resistance to Antimicrobial Peptides , 2006, Infection and Immunity.

[78]  S. Atkinson,et al.  Quorum sensing and social networking in the microbial world , 2009, Journal of The Royal Society Interface.

[79]  Jelena S. Bezbradica,et al.  A Staphylococcus aureus regulatory system that responds to host heme and modulates virulence. , 2007, Cell host & microbe.

[80]  K. Oh,et al.  Aaptamines as sortase A inhibitors from the tropical sponge Aaptos aaptos. , 2007, Bioorganic & medicinal chemistry letters.

[81]  H. Wolf‐Watz,et al.  Salicylidene Acylhydrazides That Affect Type III Protein Secretion in Salmonella enterica Serovar Typhimurium , 2007, Antimicrobial Agents and Chemotherapy.

[82]  Cheorl-Ho Kim A Salmonella typhimurium rfaE mutant recovers invasiveness for human epithelial cells when complemented by wild type rfaE (controlling biosynthesis of ADP-L-glycero-D-mannoheptose-containing lipopolysaccharide). , 2003, Molecules and cells.

[83]  A. H. Wang,et al.  Discovery of virulence factors of pathogenic bacteria. , 2008, Current opinion in chemical biology.

[84]  M. Otto,et al.  Staphylococcus quorum sensing in biofilm formation and infection. , 2006, International journal of medical microbiology : IJMM.

[85]  H. Kalbacher,et al.  Inactivation of the dlt Operon inStaphylococcus aureus Confers Sensitivity to Defensins, Protegrins, and Other Antimicrobial Peptides* , 1999, The Journal of Biological Chemistry.

[86]  S. Narayana,et al.  Identification of novel inhibitors of bacterial surface enzyme Staphylococcus aureus Sortase A. , 2008, Bioorganic & medicinal chemistry letters.

[87]  G. Waksman,et al.  Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria , 2006, Proceedings of the National Academy of Sciences.

[88]  Eric P. Skaar,et al.  Iron-Source Preference of Staphylococcus aureus Infections , 2004, Science.

[89]  Derek S. Tan,et al.  Small-molecule inhibition of siderophore biosynthesis in Mycobacterium tuberculosis and Yersinia pestis , 2005, Nature chemical biology.

[90]  Tajalli Keshavarz,et al.  Microbial quorum sensing: a tool or a target for antimicrobial therapy? , 2009, Biotechnology and applied biochemistry.

[91]  A. Alanis,et al.  Resistance to antibiotics: are we in the post-antibiotic era? , 2005, Archives of medical research.

[92]  A. Maresso,et al.  Sortase as a Target of Anti-Infective Therapy , 2008, Pharmacological Reviews.